Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.
By J. Rossouw, R. Prentice, JoAnn E. Manson, Lieling Wu, D. Barad, V. Barnabei, M. Ko, A. LaCroix, K. Margolis, M. Stefanick. Journal of the American Medical Association (JAMA), 2007
1,615 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/14362657e5363a1b722bd97b108cb5a7cbdb9fd8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Genetics
In Public Health, Environmental and Occupational Health
Citations in the corpus
- Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men (2014, background): “[26–29] The mechanisms linking estrogens to thrombotic events may be related to markers of activated coagulation, decreased coagulation inhibitors, and activated protein C resistance [30].”
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality (2010, positive): “The Women’s Health Initiative in postmenopausal women did not demonstrate a cardiovascular benefit overall from hormone therapy,(33) but younger women going through natural menopause may derive such benefit.(33,34) It is possible that BRCA1/2 mutation carriers undergoing abrupt surgical menopause to”
- The 2012 Hormone Therapy Position Statement of The North American Menopause Society (2012, positive): “Secondary analyses of the WHI data indicate that the disparity in findings between observational studies and RCTs is related partly to the timing of initiation of HT in relation to age and proximity to menopause.(36,37) Most participants in the observational studies of CHD risk were younger than 55 ”
- Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. (2015, background): “Lung cancer In the 50- to 59-year age group in the WHI study, the incidence of lung cancer was not significantly increased or decreased in either treatment arm (44).”